Wang et al., 1995 - Google Patents
Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease.Wang et al., 1995
View PDF- Document ID
- 1099265897043807870
- Author
- Wang Y
- Rollins S
- Madri J
- Matis L
- Publication year
- Publication venue
- Proceedings of the National Academy of Sciences
External Links
Snippet
Activated components of the complement system are potent mediators of inflammation that may play an important role in numerous disease states. For example, they have been implicated in the pathogenesis of inflammatory joint diseases including rheumatoid arthritis …
- 201000010099 disease 0 title abstract description 36
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. | |
| US5741488A (en) | Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies | |
| Sheehan et al. | Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. | |
| GIROIR | Mediators of septic shock: new approaches for interrupting the endogenous inflammatory cascade | |
| Williams et al. | Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. | |
| Pullerits et al. | High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis | |
| Lan et al. | Interleukin-1 receptor antagonist halts the progression of established crescentic glomerulonephritis in the rat | |
| Heremans et al. | Essential role for natural killer cells in the lethal lipopolysaccharide‐induced Shwartzman‐like reaction in mice | |
| Kavanaugh | Anti-tumor necrosis factor-α monoclonal antibody therapy for rheumatoid arthritis | |
| Machold et al. | Adalimumab–a new TNF-α antibody for treatment of inflammatory joint disease | |
| Hom et al. | The progression of the inflammation in established collagen‐induced arthritis can be altered by treatments with immunological or pharmacological agents which inhibit T cell activities | |
| EA003675B1 (en) | Interleukin-18 binding proteins, their preparation and use | |
| UA85531C2 (en) | Use of il-18 inhibitor for treatment or prevention of sepsis related cardiac dysfunction | |
| MX2008011735A (en) | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement. | |
| EA005583B1 (en) | Use of il-18 inhibitors | |
| JP2005027653A (en) | Evaluation and treatment of patient with progressive immunosuppression | |
| WO1995009652A1 (en) | Treatment of autoimmune and inflammatory disorders | |
| Keogan et al. | Anti-neutrophil cytoplasm antibodies (ANCA) increase neutrophil adhesion to cultured human endothelium | |
| Mizuno et al. | Comparison of the suppressive effects of soluble CR1 and C5a receptor antagonist in acute arthritis induced in rats by blocking of CD59 | |
| JP3892902B2 (en) | Use of antibodies to block the action of gram positive bacteria and mycobacteria | |
| Taylor et al. | Transfer of type II collagen‐induced arthritis from DBA/1 to severe combined immunodeficiency mice can be prevented by blockade of Mac‐1 | |
| AU2001261743B2 (en) | Methods for reducing tumor growth and metastasis by inhibiting MCP-1 activity | |
| US20070253961A1 (en) | Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis | |
| Bussolati et al. | Interleukin-12 is synthesized by mesangial cells and stimulates platelet-activating factor synthesis, cytoskeletal reorganization, and cell shape change | |
| Hainline et al. | Active immunotherapy for C5a-mediated inflammation using adjuvant-free self-assembled peptide nanofibers |